Back |
home / stock / aqxp / aqxp message board
Subject | By | Source | When |
---|---|---|---|
Nearly 100m cash on hand. Great bottom imo. | TheAnnointedOne | investorshub | 06/28/2018 11:27:41 AM |
The Baker Bros may double up their pos | ~MulaGreen~ | investorshub | 06/27/2018 5:53:26 PM |
You hit the nail on the head. | TheAnnointedOne | investorshub | 06/27/2018 4:44:19 PM |
Thinking the same. | TheAnnointedOne | investorshub | 06/27/2018 4:38:31 PM |
Seems like an obvious buy here at $2.30s | KOmani | investorshub | 06/27/2018 2:30:08 PM |
Insider purchases yesterday | diegonalesso | investorshub | 01/10/2017 7:28:51 AM |
Why is this Board so quiet... | Options2Wealth | investorshub | 01/10/2017 7:20:19 AM |
gains go to nvax,,sgmo $$$ | kingsransome | investorshub | 09/22/2016 6:20:29 PM |
mm r shorting the offering,,,gonna drop big nxt | kingsransome | investorshub | 09/19/2016 10:34:18 PM |
BB boyz will take it $50+ myop hold | kingsransome | investorshub | 09/14/2016 2:07:52 PM |
Baker Brothers doing well with their investment here. | crudeoil24 | investorshub | 09/13/2016 3:02:02 PM |
Let's short the piss out of this. That's | ven69 | investorshub | 09/02/2016 1:23:28 PM |
News, Short Squeeze, Breakout and More Instantly...
Aquinox Pharmaceuticals Inc. Company Name:
AQXP Stock Symbol:
NASDAQ Market:
Aquinox Pharmaceuticals Inc. Website:
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP),...
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable t...